KHRN.H — Khiron Life Sciences Income Statement
0.000.00%
HealthcareMicro Cap
Annual income statement for Khiron Life Sciences, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2017 May 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.892 | 9.58 | 8.02 | 12.8 |
Cost of Revenue | |||||
Gross Profit | — | 0.297 | 2.44 | 1.48 | 2.37 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.045 | 20.8 | 47.3 | 31.6 | 48.3 |
Operating Profit | -0.045 | -19.9 | -37.7 | -23.6 | -35.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.045 | -19.7 | -36.4 | -23.9 | -33.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.045 | -19.8 | -36.4 | -24 | -33.1 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.045 | -19.8 | -36.4 | -24 | -33.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.045 | -19.8 | -36.4 | -24 | -33.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.236 | -0.408 | -0.357 | -0.23 | -0.158 |